Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Change in Accured Expenses (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Change in Accured Expenses for 16 consecutive years, with $958000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 333.48% to $958000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 724.76% increase, with the full-year FY2024 number at -$2.9 million, down 176.95% from a year prior.
  • Change in Accured Expenses was $958000.0 for Q3 2025 at Xtant Medical Holdings, up from $23000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.7 million in Q1 2025 to a low of -$1.6 million in Q3 2021.
  • A 5-year average of $243526.3 and a median of $221000.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 10636.36% in 2021, then crashed 788.78% in 2024.
  • Xtant Medical Holdings' Change in Accured Expenses stood at $270000.0 in 2021, then surged by 75.93% to $475000.0 in 2022, then soared by 198.74% to $1.4 million in 2023, then tumbled by 175.55% to -$1.1 million in 2024, then surged by 189.37% to $958000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Change in Accured Expenses are $958000.0 (Q3 2025), $23000.0 (Q2 2025), and $2.7 million (Q1 2025).